Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.
Sara AlosaimyAbdalhamid M LagnfTaylor MorrisetteMarco R ScipioneJing J ZhaoSarah C J JorgensenRyan MynattTravis J CarlsonJinhee JoKevin W GareyDavid AllenKailynn DeRondeAna D VegaLilian M AbboVeena VenugopalanVasilios AthansStephen SawKimberly C ClaeysMathew MillerKyle C MolinaMichael VeveWesley D KufelLee AmayaChristine YostJessica OrtwineSusan L DavisMichael Joseph RybakPublished in: Open forum infectious diseases (2021)
Our results support current evidence establishing positive clinical and safety outcomes of MEV in GNIs, including CRE. We suggest that delaying appropriate therapy for CRE significantly increases the risk of NCOs.